Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19262096 | 0.86 | FFAR4 (0.37) | FFAR4SLC6A4HTR2AKCNH2CYP1A2 | |
| SCHEMBL17449715 | 0.82 | KCNH2 (0.41) | FFAR4ATML3MBTL1SLC6A4KCNH2 | |
| SCHEMBL16373805 | 0.81 | FFAR4 (0.44) | FFAR4SLC6A4HTR2AKCNH2CNR2 | |
| SCHEMBL21266901 | 0.81 | FFAR4 (0.41) | FFAR4L3MBTL1SLC6A4HTR2AKCNH2 | |
| SCHEMBL23434994 | 0.80 | HTR2A (0.49) | L3MBTL1SLC6A4HTR2AKCNH2GAA | |
| SCHEMBL4477210 | 0.78 | MAPT (0.53) | FFAR4PTGDR2SLC6A4CNR2ANO1 | |
| SCHEMBL4468349 | 0.78 | CCR5 (0.42) | FFAR4SLC6A4HTR2AKCNH2CNR2 | |
| SCHEMBL24459310 | 0.78 | FFAR4 (0.41) | FFAR4SLC6A4HTR2AKCNH2CNR2 | |
| SCHEMBL2662469 | 0.76 | SLC6A2 (0.49) | SLC6A4KCNH2CYP2D6SLC6A2 | |
| SCHEMBL12356955 | 0.75 | KCNK3 (0.39) | HTR2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9518000-B2 | Bicyclo [2.2.1] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163454-A1 | SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE | CCR8, RPS8, HDHD5 | FFAR4 1078/4885ATM 1555/4885PTGDR2 1959/4885 |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | GPR180, GPR88, GPBAR1 | FFAR4 54/4885ATM 4697/4885PTGDR2 82/4885 |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | FFAR4 1600/4885ATM 3987/4885PTGDR2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.